Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Rating of “Hold” from Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been assigned an average rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $70.75.

A number of brokerages recently weighed in on PBH. Jefferies Financial Group decreased their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a report on Friday, January 30th. Canaccord Genuity Group decreased their price objective on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday. Oppenheimer cut Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday. Finally, Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday.

Key Stories Impacting Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Negative Sentiment: Prestige reported fiscal Q4 earnings and revenue below expectations, with EPS of $1.23 versus the $1.39 consensus and revenue of $281.6 million versus $292.0 million expected, raising concerns about slower sales momentum and earnings execution. Prestige Consumer Healthcare: Fiscal Q4 Earnings Snapshot
• Negative Sentiment: Several law firms announced securities-fraud investigations into Prestige Consumer Healthcare following the earnings release, which can add overhang and increase investor anxiety around possible disclosure issues. Securities Fraud Investigation Into Prestige Consumer Healthcare (PBH) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
• Negative Sentiment: Canaccord Genuity cut its price target on PBH from $86 to $72, signaling a more cautious view on the company’s outlook even though it kept a Buy rating. Canaccord Genuity price target update
• Negative Sentiment: Oppenheimer downgraded Prestige Consumer Healthcare, adding to the negative analyst reaction after the earnings miss and reinforcing concerns about near-term performance. Oppenheimer downgrades Prestige Consumer Healthcare (PBH)
• Neutral Sentiment: The company’s earnings call and presentation may help investors assess whether management can defend margins and stabilize growth after the weak quarter. Prestige Consumer Healthcare Inc. (PBH) Q4 2026 Earnings Call Transcript

Prestige Consumer Healthcare Stock Performance

NYSE:PBH opened at $46.69 on Monday. The business’s 50-day moving average price is $57.87 and its two-hundred day moving average price is $61.37. Prestige Consumer Healthcare has a twelve month low of $42.62 and a twelve month high of $89.37. The stock has a market cap of $2.21 billion, a P/E ratio of 11.94, a PEG ratio of 1.51 and a beta of 0.40. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The firm had revenue of $281.62 million for the quarter, compared to analysts’ expectations of $293.64 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The business’s quarterly revenue was down 5.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.32 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, equities analysts predict that Prestige Consumer Healthcare will post 4.43 EPS for the current fiscal year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the transaction, the vice president directly owned 42,820 shares of the company’s stock, valued at $2,354,671.80. The trade was a 2.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Large investors have recently bought and sold shares of the stock. UMB Bank n.a. increased its stake in Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after purchasing an additional 219 shares during the period. Bayforest Capital Ltd purchased a new position in Prestige Consumer Healthcare in the 4th quarter worth approximately $29,000. First Horizon Corp purchased a new position in Prestige Consumer Healthcare in the 3rd quarter worth approximately $32,000. Barrow Hanley Mewhinney & Strauss LLC increased its stake in Prestige Consumer Healthcare by 106.8% in the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock worth $34,000 after purchasing an additional 283 shares during the period. Finally, Geneos Wealth Management Inc. increased its stake in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).